<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828659</url>
  </required_header>
  <id_info>
    <org_study_id>APD356-013</org_study_id>
    <nct_id>NCT00828659</nct_id>
  </id_info>
  <brief_title>Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users</brief_title>
  <official_title>A Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the abuse potential of lorcaserin in healthy
      recreational polydrug users.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the abuse potential of lorcaserin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of lorcaserin</measure>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Drug Abuse</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator #2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator #3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin Dose #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin Dose #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lorcaserin Dose #3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator #1</intervention_name>
    <arm_group_label>Active Comparator #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator #2</intervention_name>
    <arm_group_label>Active Comparator #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator #3</intervention_name>
    <arm_group_label>Active Comparator #3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin Dose #1</intervention_name>
    <arm_group_label>Lorcaserin Dose #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin Dose #2</intervention_name>
    <arm_group_label>Lorcaserin Dose #2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorcaserin Dose #3</intervention_name>
    <arm_group_label>Lorcaserin Dose #3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          1. Healthy male or female subjects 18 to 55 years of age, inclusive.

          2. Body mass index (BMI) within the range of 18 to 33 kg/m2, inclusive, and a minimum
             weight of at least 50 kg at Screening.

          3. Free from any clinically significant medical or psychiatric abnormality

          4. Recreational polydrug user with a history of psychedelic and depressant drug use,and
             at least one occasion of use in the past 3 months.

          5. Female subjects must have a negative serum pregnancy test at Screening and urine
             pregnancy test at each admission.

          6. Female subjects of childbearing potential must be practising abstinence or using and
             willing to continue using a medically acceptable form of birth control for at least 1
             month after the last study drug administration. Male subjects who have female partners
             of childbearing potential must ensure that their partner use an acceptable method of
             contraception.

          7. Willingness to take a drug that might alter perception in a controlled setting.

        EXCLUSION CRITERIA

        A subject will not be considered eligible to participate in this study, if any one of the
        following exclusion criteria is satisfied:

          1. A history or presence of drug or alcohol dependence (excluding nicotine and caffeine).

          2. Use of non-prescription, prescription medication or natural health products (except
             acetaminophen, vitamin or mineral supplements, acceptable forms of birth control, and
             hormone replacement) within 7 days prior to first drug administration in the
             qualification phase and throughout the study.

          3. Use of SSRIs (e.g. fluoxetine, paroxetine, citalopram) within 14 days prior to first
             drug administration in the qualification phase and throughout the study.

          4. History of allergy or hypersensitivity to the study drugs

          5. Female subjects who are currently pregnant or lactating or who are planning to become
             pregnant within 30 days of last study drug administration

          6. Treatment with any investigational drug within 30 days prior to first drug
             administration during the qualification phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kendle Early Phase, Toronto</name>
      <address>
        <city>Tronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>July 27, 2009</last_update_submitted>
  <last_update_submitted_qc>July 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christen Anderson, MD, PhD</name_title>
    <organization>Arena Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <keyword>Abuse potential</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

